2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Sameer Parikh, MD, hematologist, Mayo Clinic, discusses the utilization and significance of the Chronic Lymphocytic Leukemia (CLL)-International Prognostic Index (IPI).
Sameer Parikh, MD, hematologist, Mayo Clinic, discusses the utilization and significance of the Chronic Lymphocytic Leukemia (CLL)-International Prognostic Index (IPI).
One of the most important contributions to the landscape of CLL has been the development of the CLL-IPI, Parikh explains. This combines 5 different factors, including age, clinical stage, TP53 mutation status, IGVH mutation status, and serum β2-microglobulin concentration.
The CLL-IPI allows physicians to prognosticate when patients are going to require therapy for their CLL. This is especially emphasized for all patients with CLL, specifically those who are newly diagnosed.